Innovative Biotherapeutics Affibody specializes in next-generation biotherapeutics utilizing proprietary platforms such as Affibody® molecules and Albumod™, presenting opportunities to collaborate on novel treatments and diagnostic tools in the biotech and pharmaceutical sectors.

Strategic Collaborations Active partnerships with major industry players like Alexion, Daiichi Sankyo, and GE Healthcare highlight open avenues for joint development, licensing, and commercialization of advanced therapies, especially in autoimmune, respiratory, and cancer indications.

Clinical Stage Focus With three ongoing clinical programs targeting psoriasis, autoimmune diseases, and metastatic breast cancer, there is potential to identify customer needs in clinical development services, research collaborations, or early-stage therapeutic investments.

Growth and Funding Having secured $21 million in funding and a modest revenue base, Affibody presents an opportunity for investors or partners interested in early-stage biotech innovations and expanding biopharmaceutical pipelines.

Leadership and Talent The recent appointment of a Chief Business Officer and the company's focus on expanding its innovative pipeline suggest a growth-oriented environment suitable for strategic partnerships, licensing deals, and business development initiatives.